在意大利道中评估风险的可接受性和承受性,使用量子 Gu@larp 模型
Massimo Guarascio1, Emin Alakbarli1, Carlota Despabeladera1
1Faculty of Civil and Industrial Engineering Sapienza, Via Eudossiana 18, 00184 Rome, Italy.
Entropy (Basel, Switzerland)
|January 22, 2024
概括
本研究评估了意大利公路道的风险指标,包括风险量和社会风险. 它应用量子Gu@larp模型来评估风险的可接受性和耐受性,以提高安全性.
科学领域:
- 土木工程 土木工程是指土木工程.
- 风险管理 风险管理
- 运输安全运输安全
背景情况:
- 道路道存在重大风险,如事故和火灾,影响用户.
- 关键风险指标 (风险量,个人风险,社会风险,预期死亡人数) 对于风险评估至关重要.
- 这些指标使利益相关者能够管理危险并实施安全措施.
研究的目的:
- 在意大利道路道的背景下分析风险指标.
- 应用量子 Gu@larp 模型来评估风险的可接受性和耐受性.
- 提高对道安全风险评估的理解.
主要方法:
- 使用关键风险指标:风险量,个人风险,社会风险,预期死亡人数.
- 使用量子 Gu@larp 模型进行分析.
- 识别,描述和概率化定量风险分析的设计场景.
主要成果:
- 设计场景的风险量具有决定性和概率性特征.
- 风险承受性和可接受性标准是使用风险指标,伦理原则和社会政策来建模的.
- 该研究为了解意大利公路道中的风险指标提供了一个框架.
结论:
- 风险指标是道路道综合风险评估过程中不可或缺的一部分.
- 量子Gu@larp模型提供了一种评估风险可接受性和可容忍性的方法.
- 有效的风险管理对于确保道路道用户的安全至关重要.
相关概念视频
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
01:15Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).